GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » Cyclically Adjusted Book per Share

Oncternal Therapeutics (FRA:GTU) Cyclically Adjusted Book per Share : €62.28 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Oncternal Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Oncternal Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was €7.127. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €62.28 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Oncternal Therapeutics's average Cyclically Adjusted Book Growth Rate was -31.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -37.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -29.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -24.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Oncternal Therapeutics was 13.30% per year. The lowest was -37.40% per year. And the median was -20.10% per year.

As of today (2024-05-24), Oncternal Therapeutics's current stock price is €5.32. Oncternal Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €62.28. Oncternal Therapeutics's Cyclically Adjusted PB Ratio of today is 0.09.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Oncternal Therapeutics was 7.73. The lowest was 0.01. And the median was 0.50.


Oncternal Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Oncternal Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics Cyclically Adjusted Book per Share Chart

Oncternal Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 590.43 380.80 271.19 145.85 93.22

Oncternal Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.58 104.22 98.61 93.22 62.28

Competitive Comparison of Oncternal Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Oncternal Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncternal Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's Cyclically Adjusted PB Ratio falls into.



Oncternal Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncternal Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=7.127/131.7762*131.7762
=7.127

Current CPI (Mar. 2024) = 131.7762.

Oncternal Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 207.182 100.560 271.498
201409 151.713 100.428 199.070
201412 144.258 99.070 191.883
201503 146.475 99.621 193.753
201506 -278.199 100.684 -364.110
201509 38.317 100.392 50.296
201512 17.024 99.792 22.480
201603 210.064 100.470 275.518
201606 162.153 101.688 210.132
201609 108.859 101.861 140.829
201612 165.834 101.863 214.534
201703 115.762 102.862 148.302
201706 65.884 103.349 84.006
201709 253.929 104.136 321.329
201712 210.119 104.011 266.209
201803 124.719 105.290 156.093
201806 198.672 106.317 246.247
201809 154.459 106.507 191.106
201812 133.597 105.998 166.087
201903 107.235 107.251 131.757
201906 26.412 108.070 32.206
201909 21.421 108.329 26.057
201912 16.743 108.420 20.350
202003 12.223 108.902 14.790
202006 9.833 108.767 11.913
202009 11.929 109.815 14.315
202012 38.050 109.897 45.625
202103 36.857 111.754 43.460
202106 34.460 114.631 39.614
202109 32.494 115.734 36.998
202112 31.555 117.630 35.350
202203 29.463 121.301 32.007
202206 26.848 125.017 28.300
202209 24.940 125.227 26.244
202212 20.032 125.222 21.081
202303 16.700 127.348 17.281
202306 14.203 128.729 14.539
202309 11.757 129.860 11.931
202312 9.348 129.419 9.518
202403 7.127 131.776 7.127

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Oncternal Therapeutics  (FRA:GTU) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oncternal Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.32/62.28
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Oncternal Therapeutics was 7.73. The lowest was 0.01. And the median was 0.50.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Oncternal Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncternal Therapeutics (FRA:GTU) Business Description

Industry
Traded in Other Exchanges
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Oncternal Therapeutics (FRA:GTU) Headlines

No Headlines